医学
舒尼替尼
伊马替尼
主旨
内科学
甲磺酸伊马替尼
间质瘤
酪氨酸激酶抑制剂
肿瘤科
胃肠病学
间质细胞
PDGFRA公司
酪氨酸激酶
靶向治疗
不利影响
癌症研究
作者
Xinhua Zhang,Yulong He
出处
期刊:PubMed
日期:2015-04-01
卷期号:18 (4): 325-7
标识
DOI:10.3760/cma.j.issn.1671-0274.2015.04.007
摘要
The emergence of small molecular tyrosine kinase inhibitors opened the era of targeted therapy of gastrointestinal stromal tumor(GIST). Survival and life of quality of patients from advanced stage are significantly improved by using targeted therapy. However, with prolonged treatment, drug resistance is becoming more and more common and directly affects the survival of patients. The current clinical management in failure of multi-line targeted therapies will be discussed in this article.
科研通智能强力驱动
Strongly Powered by AbleSci AI